Evidence map›Paper›PMID 42848150›Full record

ReviewMedical oncology (Northwood, London, England)2026

RBM protein family: Focusing on the occurrence, progression and treatment of cancer.

Huhu Zhang, Wenxin Zheng, Lingxi Li, Chenhui Geng, Yuxiang Wang, Jianyu Zhang, Yulan Sun, Xuanyu Zhang, Bing Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huhu Zhang *Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Wenxin Zheng *Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Lingxi LiDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Chenhui GengDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Yuxiang WangDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Jianyu ZhangDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Yulan SunDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Xuanyu ZhangDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China.
Bing LiDepartment of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, Shandong, China. libing_516@qdu.edu.cn.ORCID https://orcid.org/0000-0002-5545-9674

Funding

Grants from the National Natural Science Foundation of China No.81871231Qingdao Natural Science Foundation Key Project 24-8-4-zrjj-8-jchScience and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China No.2019KJK016Shandong Taishan Scholars Young Experts Program No.tsqn202103056The Natural Science Foundation of Shandong Province No.ZR2023MH082
6 · The paper itself

Abstract

The RNA-binding motif (RBM) protein family plays a crucial role in regulating RNA metabolism, including transcription, splicing, stability, and translation. Dysregulation of RBM proteins has been increasingly implicated in the initiation, progression, and therapeutic resistance of various cancers. This review summarizes current knowledge on the RBM protein family, with a focus on their involvement in alternative splicing and m6A RNA methylation-two key post-transcriptional mechanisms that influence cancer biology. Members such as RBM5 and RBM10 function as tumor suppressors by modulating apoptosis, cell cycle, and splicing of oncogenic transcripts, while others like RBM15 and RBM15B contribute to tumorigenesis through m6A modification and downstream signaling pathways. The dual roles of certain RBM proteins in different cancer contexts highlight their complexity and potential as both biomarkers and therapeutic targets. Further investigation into the molecular mechanisms of RBM proteins may provide new insights for cancer diagnosis and treatment strategies.

Indexed as

NeoplasmsRNA-Binding ProteinsAlternative SplicingAnimalsBiomarkers, TumorCell Cycle ProteinsDisease ProgressionDNA-Binding ProteinsHumansRNA MethylationTumor Suppressor ProteinsBiomarkers, TumorCell Cycle ProteinsDNA-Binding ProteinsRBM5 protein, humanRNA-Binding ProteinsTumor Suppressor ProteinsAlternative splicingBiomarkerCancerm6A methylationOncogeneRBM protein familyRNA-binding proteinsTargeted therapyTherapeutic targetTumor suppressor

Identifiers

PMID42848150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.